02.22.2021 | CARB-X is funding The University of Queensland to develop a new drug targeted to low- and middle-income countries that would breathe new life into existing readily-available antibiotics in the fight against drug-resistance
CARB-X is awarding up to US$2.2 million to The University of Queensland’s (UQ) Institute for Molecular Bioscience (IMB) to expand its Octapeptin research program to develop a new drug designed for use in low- and middle-income countries (LMICs) where there are high levels of drug-resistant bacteria.
02.03.2021 | CARB-X is funding French biotech Mutabilis to develop a new class of antibacterials to treat infections caused by Carbapenem-resistant Enterobacterales (CRE) bacteria
CARB-X is awarding Mutabilis, a biopharmaceutical firm based in Romainville, France, up to US$6.4 million to develop a new drug to treat infections caused by Carbapenem-resistant Enterobacterales (CRE) bacteria.
02.01.2021 | CARB-X is funding the development of Avails Medical’s rapid antibiotic susceptibility testing technology to identify the most effective antibiotic therapy for serious blood infections
CARB-X is funding Avails Medical, a Menlo Park, CA, USA, diagnostics company, to develop an electronic antibiotic susceptibility testing (AST) device to speed up health care providers’ ability to determine the most effective antibiotic treatment for serious and life-threatening blood infections.
01.27.2021 | CARB-X is funding Seattle-based Lumen Bioscience to develop a new oral monoclonal antibody cocktail to prevent serious diarrheal diseases
CARB-X is awarding up to US$5.35 million to Lumen Bioscience, in Seattle, WA, USA, to develop a new immunotherapy to prevent diarrheal diseases caused by two deadly pathogens, Campylobacter jejuni and enterotoxigenic E. coli.